Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Myron Bednar (NPI 1235127622)

Field	Value
Entity Type	Individual
Organization	Myron Bednar
Address	2100 Wescott Dr
City	Flemington
State	NJ
ZIP	08822
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 10, 2005

Payer Source	Total Paid
Medicare	$2.5M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused hematology/oncology practice with Total Medicare revenue of $2.5M and no Medicaid billing on file, meaning the clinician operates as a single‑payer (Medicare) provider in the available data. The absence of any Medicaid claims suggests negligible participation in state Medicaid programs rather than a mixed payer model.

Revenue concentration is high and driven by a small set of biologic/oncology agents: the precomputed top 3 Medicare codes (J9271, J0897, J9299) account for 60.2% of this provider's total Medicare revenue. Those three line items are J9271 ($679.4K, 27.9%), J0897 ($401.2K, 16.5%), and J9299 ($384K, 15.8%), indicating most dollars flow through high-cost injections rather than routine office-based services.

The code mix indicates an infusion-centric oncology operation: J9271 (pembrolizumab), J9299 (nivolumab) and J0897 (denosumab) are immune checkpoint inhibitors and bone-targeting biologics commonly administered in infusion settings, and additional chemotherapy and infusion codes such as 96413 and 96365/96367 appear in the top list. Supportive therapies and biologics are also present (J1568 IVIG, J2506 pegfilgrastim, J1449 eflapegrastim), reinforcing that the practice provides both systemic cancer therapy and associated supportive care on site.

Competitive standing is mixed across codes: the provider is a notably high-volume national participant for J0897 (rank #224 of 10057, 98th percentile; described as notably above typical national volume) and shows strong national activity for chemotherapy administration codes (96413 ranks #175 of 7514, 98th percentile; notably above typical national volume). By contrast, the provider’s J9271 activity is more typical for the nation (rank #627 of 1841, 66th percentile), and J9299 likewise sits at a typical volume (rank #224 of 505, 56th percentile), so dominance is concentrated in specific biologics rather than across all oncology drugs.

Several utilization metrics are statistical outliers versus national peers and point to unusually high visit or procedure throughput in specific areas: 99213 is an extreme outlier (rank #3215 of 457151, 99th percentile; far above typical national volume), and 96372 is also flagged as an extreme outlier (rank #173 of 58224, 100th percentile). These outlier labels suggest this clinician bills far more low-level E/M visits and routine injections than most peers in the national Medicare dataset.

Operational patterns implied by the CPT mix show both high-cost drug administration and a substantial volume of lower‑paid, high-count services: for example J1439 appears with 58.5K claims at $1 avg paid/claim for $58.5K revenue, while high-revenue items like J9271 and J9299 drive hundreds of thousands in revenue. This split—large claim counts at low unit payment alongside concentrated high-dollar biologic administrations—indicates a practice balancing frequent supportive procedures with episodic, high-value oncology infusions.

Tenure and stability: the provider’s NPI was enumerated on 2005-10-10 (~21 years ago), which suggests long-standing Medicare enrollment and an established clinical presence in Flemington, NJ. That duration supports interpretation of observed patterns as sustained practice behavior rather than a short-term billing anomaly.

Service-line implications for payers and network strategy: because roughly 60.2% of Medicare revenue is tied to three infusion biologics (J9271, J0897, J9299), contracting or utilization-management strategies aimed at oncology drug pathways and infusion site-of-care could materially affect this provider’s Medicare spend. Additionally, the lack of Medicaid activity means state-level managed care strategies would have limited direct impact on this clinician’s billed Medicaid dollars, while Medicare-focused clinical pathways and step-therapy policies are likely to be more relevant.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

66 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,800	$40	$679.4K
J0897	Injection, denosumab, 1 mg	22,290	$20	$401.2K
J9299	Injection, nivolumab, 1 mg	16,000	$20	$384K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	5,890	$30	$200.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,310	$80	$98K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	800	$120	$98K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	3,230	$30	$80.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	740	$110	$78.2K
J3111	Injection, romosozumab-aqqg, 1 mg	9,350	$10	$74.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	740	$90	$66.1K

Showing 1–10 of 66

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 66 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Myron Bednar — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

66 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	50	10,650	$40	$580.7K
J9299	3	10	23,410	$20	$565.3K
J1568	2	10	5,220	$30	$445.1K
J3111	19	30	12,600	$10	$107.3K
J1449	6	10	3,140	$30	$96.4K
J0897	7	380	3,060	$20	$87.8K
82306	66	250	50	$30	$79K
84443	178	380	100	$20	$65.5K
80053	35	560	90	$10	$50.8K
J2506	4	20	400	$80	$44.4K

Showing 1–10 of 66

Related Providers

Other providers that share a Tax Identification Number (TIN) with Myron Bednar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Megha Shah	NJ	Hematology & Oncology Physician	$964.3K	$0
Waqas Rehman	NJ	Hematology & Oncology Physician	$760.4K	$0
Edward Soffen	NJ	Radiation Oncology Physician	$714.2K	$0
Kenneth Blankstein	NJ	Hematology & Oncology Physician	$573.9K	$0
Victor Ng	NJ	Radiation Oncology Physician	$254.6K	$0
Andrew Greenberg	NJ	Radiation Oncology Physician	$253.3K	$0

Nearby Providers

Other providers in the same ZIP code as Myron Bednar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hunterdon Medical Center	NJ	General Acute Care Hospital	$0	$40.3M
Coaching For Independence	NJ	Community/Behavioral Health Agency	$0	$11.7M
Catholic Charities, Diocese Of Metuchen	NJ	Community/Behavioral Health Agency	$0	$10.5M
Hunterdon Orthopedic Institute PA	NJ	Orthopaedic Surgery Physician	$0	$9.8M
Easter Seals New Jersey	NJ	Mental Illness Community Based Residential Treatment Facility	$0	$8.8M
High Point Partial Care, LLC	NJ	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$8.8M
Hunterdon Endosurgery Center	NJ	Ambulatory Surgical Clinic/Center	$614.3K	$829.2K
Hunterdon Center For Surgery, LLC	NJ	Ambulatory Surgical Clinic/Center	$853.9K	$338K
Andrey Espinoza	NJ	Cardiovascular Disease Physician	$888.2K	$0
Neal Varughese	NJ	Dermatology Physician	$468.2K	$0

Myron Bednar — Billing Profile & Reimbursement Data

Sign up for Myron Bednar — Billing Profile & Reimbursement Data policy alerts

Myron Bednar — Billing Profile & Reimbursement Data

Sign up for Myron Bednar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References